Quality of Reporting Noninferiority and Equivalence Trials in Glaucoma
Author Information
Author(s): Eyawo Oghenowede, Lee Chia-Wen, Rachlis Beth, Mills Edward J
Primary Institution: Faculty of Health Sciences, Simon Fraser University
Hypothesis
What is the reporting quality of prostaglandin noninferiority and equivalence trials in the treatment of glaucoma?
Conclusion
The quality of reporting noninferiority/equivalency trials in the field of glaucoma is markedly heterogeneous.
Supporting Evidence
- 36% of the trials were crossover designs.
- Only 6% of studies reported results for both ITT and PP populations.
- 72% of studies adequately described their margin of noninferiority/equivalence.
Takeaway
This study looked at how well trials for glaucoma treatments reported their methods and results, and found that many did not follow the best practices.
Methodology
A systematic survey of the literature was conducted to identify noninferiority and equivalence randomized clinical trials involving glaucoma drugs of prostaglandin origin.
Potential Biases
Potential bias due to reliance on reported data without verification from trial authors.
Limitations
The study relied on the reporting of specific items rather than contacting trial investigators for missing information.
Statistical Information
Confidence Interval
95% CI: 24–51
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website